Abstracts tagged "Infection"

Abstract Number: 1359 • ACR Convergence 2021
Risk of Respiratory Tract Infections with Biologic and Targeted Synthetic Antirheumatic Agents in Psoriatic Arthritis: A Systematic Review and Network Meta-analysis
Yi-Shao Liu¹, Jawad Bilal², Muhammad Ajmal², Syed Arsalan Ahmed Naqvi³, Zaina Shahid⁴, Kaneez Zahra Rubab Khakwani², Farva Gondal⁵, Irbaz Bin Riaz⁶, Sandipan Bhattacharjee¹, Roxanne Bogucka¹ and C. Kent Kwoh⁷, ¹University of Texas at Austin, Austin, TX, ²University of Arizona, Tucson, AZ, ³Dow University of Health Sciences, Karachi, Pakistan, ⁴Lehigh Valley Health Network, Allentown, PA, ⁵University of Arizona College of Medicine, Tucson, AZ, ⁶Mayo Clinic, Phoenix, AZ, ⁷University of Arizona College of Medicine, Tuscon, AZ
Background/Purpose: A variety of biologic and targeted synthetic disease modifying antirheumatic agents have been widely used among patients with psoriatic arthritis (PsA). Due to the…
Abstract Number: 1783 • ACR Convergence 2021
National Trends in Hospitalizations for Serious Infections in People with Psoriatic Arthritis Using the National Inpatient Sample 2012 – 2017
Vagishwari Murugesan¹, Eleni Pilitsi², Gabriela Rabasa³ and Maureen Dubreuil⁴, ¹Boston University Medical Center, Boston, MA, ²Boston Medical Center, Boston, MA, ³Boston University, Boston, MA, ⁴Boston University School of Medicine/ VA Boston, Boston, MA
Background/Purpose: Given that uptake of biologic therapies has increased over recent years, we sought to investigate the national trends in serious infections in patients with…
Abstract Number: 0618 • ACR Convergence 2021
Post-acute Sequelae of SARS-CoV-2 and Serological Response in a Cohort of Patients with Rheumatic Diseases
Alice Fike¹, Omer Pamuk², Yiming Luo³, Jun Chu⁴, Yanira Ruiz-Perdomo³, Sarfaraz Hasni³, Pravitt Gourh³ and James Katz⁴, ¹National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, ²NIH/NIAMS, Bethesda, MD, ³National Institutes of Health, Bethesda, MD, ⁴National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: The longitudinal experience of COVID-19 illness in patients with rheumatic diseases is emerging. Reports from the general population have described post-acute sequelae of SARS-CoV-2…
Abstract Number: 1527 • ACR Convergence 2021
Effect of Rituximab on IgG Levels and Associated Infection Risk in Myositis
Michael Macklin¹, Chester Oddis², Siamak Moghadam-Kia², Dana Ascherman² and Rohit Aggarwal², ¹University of Pittsburgh, Pittsburgh, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Rituximab is an anti-CD20 antibody with therapeutic use in myositis. However, given its B cell depleting mechanism, there is concern regarding its association with…
Abstract Number: 1877 • ACR Convergence 2021
Takayasu Arteritis Patients with Tuberculosis Have Unique Clinical Characteristics
Yiming Luo¹, Kaitlin Quinn², Marcela Ferrada¹, Elaine Novakovich¹ and Peter Grayson³, ¹National Institutes of Health, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, ³National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: Takayasu’s arteritis (TAK) is an idiopathic inflammatory disease primarily affecting the aorta and its major branches. Mycobacterium tuberculosis is prevalent in developing countries and…
Abstract Number: 0638 • ACR Convergence 2021
Improving Safety in Rheumatology Patients by Closing Pre-screening Laboratory Care Gaps
P. Daniel Nicholas¹, Jonida Cote², Dante Grassi¹, Swana Thomas³, Joseph Chronowski¹, David Pugliese⁴ and Eric Newman¹, ¹Geisinger Medical Center, Danville, PA, ²Geisinger Medical Center, Orefield, PA, ³Geisinger Medical Center, Wilkes-Barre, PA, ⁴Geisinger Medical Center, Wilkes Barre, PA
Background/Purpose: The Centers for Disease Control and Prevention and expert rheumatologists recommend screening for HBV and HCV prior to DMARD initiation and the ACR recommends…
Abstract Number: 1528 • ACR Convergence 2021
Clinical Consequences of Hepatitis B Core Antibody Positivity After IVIG Administration
William West¹, Therese Posas-Mendoza², Jerald Zakem³, William Davis¹ and Robert Quinet⁴, ¹Ochsner Medical Center, New Orleans, LA, ²Ochsner Clinic Foundation, New Orleans, LA, ³Ochsner Health Systems, Metairie, LA, ⁴Ochsner Health, River Ridge, LA
Background/Purpose: Intravenous immunoglobulin (IVIG) is a blood product created by pooling of donor plasma that is used for a wide range of indications. IVIG is…
Abstract Number: 0639 • ACR Convergence 2021
Improving Pre-biologic Infection Screening Using a Best Practice Alert in Electronic Health Records
Hailey Baker¹, Rebecca Fine¹, Betty Hsiao², Vaidehi Chowdhary³, Lisa Suter⁴ and Abhijeet Danve⁵, ¹Yale University, New Haven, CT, ²Yale-New Haven Medical Center, New Haven, CT, ³Yale University, East Haven, CT, ⁴Yale School of Medicine, New Haven, CT, ⁵Yale University, Rocky Hill, CT
Background/Purpose: Biologics and small molecules (bDMARDs) are important immunomodulatory medications for management of patients with rheumatic diseases. Use of a bDMARD in patients with infection…
Abstract Number: 1534 • ACR Convergence 2021
Severity Factors of Covid-19 Infection in Rheumatic Immune-mediated Inflammatory Diseases: Study in a Single University Hospital
David Martinez-Lopez¹, Diana Prieto-Peña¹, Lara Sánchez-Bilbao¹, Carmen Álvarez-Reguera¹, Alba Herrero-Morant¹, Fabricio Benavides-Villanueva¹, Cristina Corrales-Selaya¹, Martin Trigueros-Vazquez¹, Miguel Ángel gonzalez-Gay², Ricardo Blanco³ and Reinhard Wallmann⁴, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ³Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴Cantabria Health Service, Santander, Spain
Background/Purpose: Severity factors for COVID-19 have been widely studied in the general population. However, the severity factors and characteristics of COVID-19 in patients with rheumatic…
Abstract Number: 0648 • ACR Convergence 2021
Improving Post-Rituximab Hypogammaglobulinemia Risk Assessments: A Fellows’ Quality Improvement Initiative
Beth Rutstein¹, Melissa Argraves², Atiye Bilgic Dagci², Sarah Bayefsky², Julia Rood², Julie Chase³, Jay Mehta², Melissa Lerman², Cory Stingl⁴ and Jon Burnham², ¹Children's Hospital of Philadelphia, Wynnewood, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³The Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Children's Hospital of Philadelphia, Durham, NC
Background/Purpose: Hypogammaglobulinemia following rituximab therapy is a potentially severe complication that can lead to infection-related morbidity and mortality. If recognized, clinicians may prevent infections by…
Abstract Number: 1542 • ACR Convergence 2021
Does Adjustment to Dosing and Timing of Immunomodulatory Drugs Impact Immunogenicity of COVID19 Vaccines in Patients with Autoimmune and Inflammatory Rheumatic Disease (AIIRD)?
Andrew Laster¹, Gordon Lam¹, Sarah McCarter¹, Heather Gladue², Ahmad Kashif¹, Erin Siceloff¹, Victoria Lackey², Cheryl Robertson², Ashley Toci¹ and Leonard Calabrese³, ¹Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, NC, ²Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC, ³Cleveland Clinic, Cleveland, OH
Background/Purpose: Clinical trials leading to approval of the COVID19 vaccines did not include immunocompromised individuals. Concerns have been raised that immunogenicity of the vaccines may…
Abstract Number: 0802 • ACR Convergence 2021
Infection in Rheumatoid Arthritis Patients Treated with Golimumab
Louis Bessette¹, Proton Rahman², John Kelsall³, Jane Purvis⁴, Emmanouil Rampakakis⁵, Allen Lehman⁶, Meagan Rachich⁶, Francois Nantel⁷ and Odalis Asin-Milan⁶, ¹Laval University, Québec City, QC, Canada, ²Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ³Providence Health Care, Vancouver, BC, Canada, ⁴Peterborough Education, Peterborough, ON, Canada, ⁵JSS Medical Research, Montréal, QC, Canada, ⁶Janssen Inc., Toronto, ON, Canada, ⁷., Montreal, ON, Canada
Background/Purpose: Biologic use in RA is a well-characterized risk factors for infections. The aim of this analysis was to characterize the incidence of infection in…
Abstract Number: 1548 • ACR Convergence 2021
Q Fever as a Mimicker of Rheumatologic Conditions: A Case Series from Two Tertiary Care Academic Centers in Southern California
Manushi Aggarwal and Marven Cabling, Loma Linda University Health, Redlands, CA
Background/Purpose: Q fever, an endemic disease in Southern California, is a zoonosis caused by Coxiella burnetii. The infection can present with multiple non-specific acute and chronic manifestations including fever, headache,…
Abstract Number: 0010 • ACR Convergence 2021
Relaxed Peripheral Tolerance Drives Broad de Novo Autoreactivity in Severe COVID-19
Matthew Woodruff¹, Richard Ramonell², Ankur Singh Saini², Mark Rudolph³, F. Eun-Hyung Lee² and Iñaki Sanz⁴, ¹Emory University, Decatur, GA, ²Emory University, Atlanta, GA, ³Exagen Inc., Vista, CA, ⁴Emory University School of Medicine, Atlanta, GA
Background/Purpose: An emerging feature of COVID-19 is the identification of autoreactivity in patients with severe disease that may contribute to disease pathology, however the origins…
Abstract Number: 0843 • ACR Convergence 2021
Prevalence and Trends of Infections in Hospitalized Patients with Rheumatoid Arthritis in the United States
Pushti Khandwala¹, Anila Hussain² and Devashish Desai¹, ¹Crozer Chester Medical Center, Glen Mills, PA, ²Crozer Chester Medical Center, Glen Mills
Background/Purpose: Rheumatoid arthritis (RA) patients have a higher risk of developing infections as compared to the patients without the diagnosis, and this risk is further…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.